Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,048,008
  • Shares Outstanding, K 622,278
  • Annual Sales, $ 23,747 M
  • Annual Income, $ 8,394 M
  • 60-Month Beta 1.21
  • Price/Sales 5.01
  • Price/Cash Flow 10.58
  • Price/Book 9.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 3.49
  • Number of Estimates 10
  • High Estimate 3.73
  • Low Estimate 3.04
  • Prior Year 3.47
  • Growth Rate Est. (year over year) +0.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
179.01 +7.18%
on 03/08/19
192.52 -0.34%
on 03/18/19
+4.89 (+2.62%)
since 02/19/19
3-Month
178.29 +7.61%
on 12/24/18
204.33 -6.10%
on 01/18/19
+6.37 (+3.43%)
since 12/19/18
52-Week
163.31 +17.48%
on 04/02/18
210.19 -8.72%
on 09/27/18
+9.31 (+5.10%)
since 03/19/18

Most Recent Stories

More News
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

BAYRY : 19.6850 (+2.58%)
REGN : 404.66 (-0.72%)
AMGN : 191.70 (+0.20%)
SNY : 44.92 (+0.02%)
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating...

CYTK : 8.47 (+2.92%)
AMGN : 191.70 (+0.20%)
Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down

Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.

SPPI : 10.51 (+0.77%)
AITB : 4.7100 (-0.32%)
INFI : 1.77 (-1.67%)
AMGN : 191.70 (+0.20%)
Corcept Therapeutics Appoints Former Amgen Development Executive, Andreas Grauer, M.D., as Chief Medical Officer

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 12.26 (-0.41%)
AMGN : 191.70 (+0.20%)
Roche Gets Approval for Label Expansion of MabThera in Europe

Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.

CELG : 88.68 (+0.78%)
NVS : 93.50 (+0.35%)
RHHBY : 33.7300 (-0.38%)
AMGN : 191.70 (+0.20%)
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke

Amgen (NASDAQ:AMGN) today announced plans to conduct VESALIUS-CV, a multinational clinical outcomes study for Repatha® (evolocumab) which will involve at least 13,000 patients worldwide at high risk of...

AMGN : 191.70 (+0.20%)
Roche Receives EC Approval for Label Expansion of Hemlibra

Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.

NVS : 93.50 (+0.35%)
ABBV : 80.90 (+0.31%)
RHHBY : 33.7300 (-0.38%)
AMGN : 191.70 (+0.20%)
After Yesterday's Rally of 1.95% Shares Could Potentially Pullback

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $185.43 to a high of $187.92. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $184.62...

AMGN : 191.70 (+0.20%)
Industry Veteran Joins Vivacitas Oncology As New Biotech CEO

Pramod Gupta, PhD fills the shoes of past CEO Dr. Joseph Rubinfeld - a co-founder of Amgen, Supergen, and Vivacitas Oncology

AMGN : 191.70 (+0.20%)
Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval

FDA approves Pfizer's (PFE) biosimilar version Roche's (RHHBY) breast cancer drug, Herceptin.

ABBV : 80.90 (+0.31%)
RHHBY : 33.7300 (-0.38%)
AMGN : 191.70 (+0.20%)
PFE : 41.97 (+0.38%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Steady.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 193.67
1st Resistance Point 192.49
Last Price 191.70
1st Support Level 190.16
2nd Support Level 189.01

See More

52-Week High 210.19
Fibonacci 61.8% 192.28
Last Price 191.70
Fibonacci 50% 186.75
Fibonacci 38.2% 181.22
52-Week Low 163.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar